<p>切维切斯信托控股公司在最近向证券交易委员会提交的 13F 文件中表示，在第二季度将其在 MaxCyte, Inc.（纳斯达克代码：MXCT - 免费报告）中的股份减少了 22.7%。该机构投资者在此期间出售了 506,943 股后，持有 1,723,239 股该公司的股票。切维切斯信托控股公司在最近的报告期末持有约 1.62% 的 MaxCyte 股份，价值 375.7 万美元。</p>
<ul>
<li>MaxCyte：构建细胞和基因治疗创新的未来</li>
</ul>
<p>其他几家大型投资者最近也增加或减少了对该股票的持股。Mudita Advisors LLP 在第一季度将其在 MaxCyte 的持股增加了 3.3%。Mudita Advisors LLP 现在持有 3,328,441 股该公司的股票，价值 908.7 万美元，此前在上个季度购买了 105,034 股。Gagnon Securities LLC 在第一季度将其在 MaxCyte 的持股增加了 431.3%。Gagnon Securities LLC 现在持有 1,048,318 股该公司的股票，价值 286.2 万美元，此前在上个季度购买了 850,992 股。Royce &amp; Associates LP 在第一季度将其在 MaxCyte 的持股增加了 30.1%。Royce &amp; Associates LP 现在持有 1,040,873 股该公司的股票，价值 284.2 万美元，此前在上个季度购买了 241,000 股。Gagnon Advisors LLC 在第一季度获得了 MaxCyte 的新股份，价值 255 万美元。最后，Rice Hall James &amp; Associates LLC 在第一季度将其在 MaxCyte 的持股增加了 72.2%。Rice Hall James &amp; Associates LLC 现在持有 454,365 股该公司的股票，价值 124 万美元，此前在上个季度购买了 190,532 股。目前 68.81% 的股票由机构投资者和对冲基金持有。</p>
<h2>内部买卖</h2>
<p>在其他消息中，首席财务官 Douglas J. Swirsky 在 8 月 13 日星期三购买了 50,000 股该公司的股票。每股平均购买价格为 1.29 美元，总交易额为 64,500.00 美元。购买完成后，首席财务官持有 161,811 股该公司的股票，价值 208,736.19 美元。这笔交易代表了他们持股的 44.72% 的增长。该购买在向证券交易委员会的文件中披露，相关信息可通过 SEC 网站获取。此外，董事 Stanley C. Erck 在 8 月 13 日星期三购买了 100,000 股该公司的股票。该股票的平均购买价格为 1.37 美元，总交易额为 137,000.00 美元。购买后，该董事直接持有 398,328 股该公司的股票，价值 545,709.36 美元。这笔交易代表了他们持股的 33.52% 的增长。该购买的披露信息可以在这里找到。内部人士在过去九十天内购买了 355,000 股公司股票，价值 479,950 美元。内部人士持有该公司 3.30% 的股票。</p>
<h2>MaxCyte 股票表现</h2>
<p>纳斯达克：MXCT 在星期二开盘价为 1.75 美元。该股票的 50 日简单移动平均为 1.51 美元，200 日简单移动平均为 2.02 美元。MaxCyte, Inc.的年低为 1.26 美元，年高为 5.20 美元。该公司的市值为 1.8656 亿美元，市盈率为-4.07，贝塔值为 1.23。</p>
<p>MaxCyte（纳斯达克：MXCT - 获取免费报告）最近在 8 月 6 日星期三发布了其财报。该公司报告季度每股收益（EPS）为（0.12 美元），低于分析师一致预期的（0.10 美元）2 美分。MaxCyte 的股本回报率为-22.12%，净利润率为-125.22%。该季度的营业收入为 851 万美元，而一致预期为 957 万美元。平均而言，股票研究分析师预测 MaxCyte, Inc.在当前财年将发布-0.42 的每股收益。</p>
<h2>分析师评级变动</h2>
<p>几位分析师最近对该公司发布了报告。华尔街 Zen 在 8 月 9 日星期六将 MaxCyte 的评级从 “持有” 下调至 “卖出”。Stephens 在 7 月 22 日星期二的研究报告中开始覆盖 MaxCyte 的股票。他们给予了 “增持” 评级，并设定了 6.00 美元的目标价。BTIG Research 在 8 月 11 日星期一的研究报告中重新发布了 MaxCyte 的 “中性” 评级。William Blair 在 8 月 7 日星期四的研究报告中将 MaxCyte 的股票评级从 “跑赢大盘” 下调至 “市场表现”。最后，Weiss Ratings 在 10 月 14 日星期二的研究报告中重新发布了 MaxCyte 的 “卖出（d-）” 评级。两位研究分析师对该股票给予了买入评级，两位给予了持有评级，一位给予了卖出评级。根据 MarketBeat 的数据，该股票目前的平均评级为 “持有”，平均目标价为 7.00 美元。</p>
<p><strong>查看我们对 MaxCyte 的最新股票分析</strong></p>
<h2>关于 MaxCyte</h2>
<p>（免费报告）</p>
<p>MaxCyte, Inc.是一家生命科学公司，在美国和国际上发现、开发和商业化下一代细胞疗法。其产品包括 ExPERT ATx，一种用于小到中型规模转染的静态电穿孔仪；ExPERT STx，一种用于蛋白质生产和药物开发的流动电穿孔仪，以及用于细胞基础检测的治疗靶标表达；ExPERT GTx，一种用于治疗应用的大规模转染的流动电穿孔仪；以及 ExPERT VLx，用于非常大体积的细胞工程。</p>
<h2>推荐阅读</h2>
<ul>
<li>我们更喜欢的五只股票胜过 MaxCyte</li>
<li>投资优先股与普通股的比较</li>
<li>路易威登财报显示奢侈品牛市尚未结束</li>
<li>如何使用 MarketBeat 股息计算器</li>
<li>3 家高收益银行供投资者在下跌时购买</li>
<li>一些最佳的大盘股有哪些？</li>
<li>5 只意外受益于未来机器人热潮的股票</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TVhDVA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TVhDVA"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 1,000 美元在 MaxCyte 吗？</h2>
<p>在你考虑 MaxCyte 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 MaxCyte 并不在名单上。</p>
<p>虽然 MaxCyte 目前在分析师中被评为持有评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

MXCT

<p>Chevy Chase Trust Holdings LLC 在第二季度减少了对 MaxCyte, Inc. (NASDAQ:MXCT) 的持股比例，下降了 22.7%，目前持有 1,723,239 股，价值 376 万美元。其他投资者，包括 Mudita Advisors 和 Gagnon Securities，增加了他们的持股。首席财务官 Douglas J. Swirsky 和董事 Stanley C. Erck 进行了大量股票购买。MaxCyte 的股票开盘价为 1.75 美元，市值为 1.8656 亿美元。该公司报告第二季度每股亏损 0.12 美元，未能达到预期，分析师对该股票的评级不一，有些将其下调至 “卖出”</p>

<p>Chevy Chase Trust Holdings LLC reduced its stake in MaxCyte, Inc. (NASDAQ:MXCT - Free Report) by 22.7% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,723,239 shares of the company's stock after selling 506,943 shares during the period. Chevy Chase Trust Holdings LLC owned approximately 1.62% of MaxCyte worth $3,757,000 at the end of the most recent reporting period.</p>
<div class="lb-trans"><p>切维切斯信托控股公司在最近向证券交易委员会提交的 13F 文件中表示，在第二季度将其在 MaxCyte, Inc.（纳斯达克代码：MXCT - 免费报告）中的股份减少了 22.7%。该机构投资者在此期间出售了 506,943 股后，持有 1,723,239 股该公司的股票。切维切斯信托控股公司在最近的报告期末持有约 1.62% 的 MaxCyte 股份，价值 375.7 万美元。</p>
</div><ul>
<li>MaxCyte: Building the Future of Cell and Gene Therapy Innovation</li>
</ul>
<div class="lb-trans"><ul>
<li>MaxCyte：构建细胞和基因治疗创新的未来</li>
</ul>
</div><p>Several other large investors have also recently added to or reduced their stakes in the stock. Mudita Advisors LLP increased its holdings in MaxCyte by 3.3% in the 1st quarter. Mudita Advisors LLP now owns 3,328,441 shares of the company's stock valued at $9,087,000 after purchasing an additional 105,034 shares in the last quarter. Gagnon Securities LLC increased its holdings in MaxCyte by 431.3% in the 1st quarter. Gagnon Securities LLC now owns 1,048,318 shares of the company's stock valued at $2,862,000 after purchasing an additional 850,992 shares in the last quarter. Royce &amp; Associates LP increased its holdings in MaxCyte by 30.1% in the 1st quarter. Royce &amp; Associates LP now owns 1,040,873 shares of the company's stock valued at $2,842,000 after purchasing an additional 241,000 shares in the last quarter. Gagnon Advisors LLC acquired a new stake in MaxCyte in the 1st quarter valued at $2,550,000. Finally, Rice Hall James &amp; Associates LLC increased its holdings in MaxCyte by 72.2% in the 1st quarter. Rice Hall James &amp; Associates LLC now owns 454,365 shares of the company's stock valued at $1,240,000 after purchasing an additional 190,532 shares in the last quarter. 68.81% of the stock is currently owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>其他几家大型投资者最近也增加或减少了对该股票的持股。Mudita Advisors LLP 在第一季度将其在 MaxCyte 的持股增加了 3.3%。Mudita Advisors LLP 现在持有 3,328,441 股该公司的股票，价值 908.7 万美元，此前在上个季度购买了 105,034 股。Gagnon Securities LLC 在第一季度将其在 MaxCyte 的持股增加了 431.3%。Gagnon Securities LLC 现在持有 1,048,318 股该公司的股票，价值 286.2 万美元，此前在上个季度购买了 850,992 股。Royce &amp; Associates LP 在第一季度将其在 MaxCyte 的持股增加了 30.1%。Royce &amp; Associates LP 现在持有 1,040,873 股该公司的股票，价值 284.2 万美元，此前在上个季度购买了 241,000 股。Gagnon Advisors LLC 在第一季度获得了 MaxCyte 的新股份，价值 255 万美元。最后，Rice Hall James &amp; Associates LLC 在第一季度将其在 MaxCyte 的持股增加了 72.2%。Rice Hall James &amp; Associates LLC 现在持有 454,365 股该公司的股票，价值 124 万美元，此前在上个季度购买了 190,532 股。目前 68.81% 的股票由机构投资者和对冲基金持有。</p>
</div><h2>Insider Buying and Selling</h2>
<div class="lb-trans"><h2>内部买卖</h2>
</div><p>In other news, CFO Douglas J. Swirsky purchased 50,000 shares of the company's stock in a transaction on Wednesday, August 13th. The shares were bought at an average price of $1.29 per share, for a total transaction of $64,500.00. Following the completion of the purchase, the chief financial officer owned 161,811 shares of the company's stock, valued at $208,736.19. This trade represents a 44.72% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities &amp; Exchange Commission, which is accessible through the SEC website. Also, Director Stanley C. Erck purchased 100,000 shares of the company's stock in a transaction on Wednesday, August 13th. The stock was purchased at an average price of $1.37 per share, for a total transaction of $137,000.00. Following the purchase, the director directly owned 398,328 shares of the company's stock, valued at $545,709.36. This trade represents a 33.52% increase in their position. The disclosure for this purchase can be found here. Insiders have acquired 355,000 shares of company stock valued at $479,950 in the last ninety days. Insiders own 3.30% of the company's stock.</p>
<div class="lb-trans"><p>在其他消息中，首席财务官 Douglas J. Swirsky 在 8 月 13 日星期三购买了 50,000 股该公司的股票。每股平均购买价格为 1.29 美元，总交易额为 64,500.00 美元。购买完成后，首席财务官持有 161,811 股该公司的股票，价值 208,736.19 美元。这笔交易代表了他们持股的 44.72% 的增长。该购买在向证券交易委员会的文件中披露，相关信息可通过 SEC 网站获取。此外，董事 Stanley C. Erck 在 8 月 13 日星期三购买了 100,000 股该公司的股票。该股票的平均购买价格为 1.37 美元，总交易额为 137,000.00 美元。购买后，该董事直接持有 398,328 股该公司的股票，价值 545,709.36 美元。这笔交易代表了他们持股的 33.52% 的增长。该购买的披露信息可以在这里找到。内部人士在过去九十天内购买了 355,000 股公司股票，价值 479,950 美元。内部人士持有该公司 3.30% 的股票。</p>
</div><h2>MaxCyte Stock Performance</h2>
<div class="lb-trans"><h2>MaxCyte 股票表现</h2>
</div><p>NASDAQ:MXCT opened at $1.75 on Tuesday. The stock has a 50-day simple moving average of $1.51 and a 200 day simple moving average of $2.02. MaxCyte, Inc. has a one year low of $1.26 and a one year high of $5.20. The company has a market capitalization of $186.56 million, a price-to-earnings ratio of -4.07 and a beta of 1.23.</p>
<div class="lb-trans"><p>纳斯达克：MXCT 在星期二开盘价为 1.75 美元。该股票的 50 日简单移动平均为 1.51 美元，200 日简单移动平均为 2.02 美元。MaxCyte, Inc.的年低为 1.26 美元，年高为 5.20 美元。该公司的市值为 1.8656 亿美元，市盈率为-4.07，贝塔值为 1.23。</p>
</div><p>MaxCyte (NASDAQ:MXCT - Get Free Report) last issued its earnings results on Wednesday, August 6th. The company reported ($0.12) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.10) by ($0.02). MaxCyte had a negative return on equity of 22.12% and a negative net margin of 125.22%.The business had revenue of $8.51 million during the quarter, compared to the consensus estimate of $9.57 million. On average, equities research analysts forecast that MaxCyte, Inc. will post -0.42 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>MaxCyte（纳斯达克：MXCT - 获取免费报告）最近在 8 月 6 日星期三发布了其财报。该公司报告季度每股收益（EPS）为（0.12 美元），低于分析师一致预期的（0.10 美元）2 美分。MaxCyte 的股本回报率为-22.12%，净利润率为-125.22%。该季度的营业收入为 851 万美元，而一致预期为 957 万美元。平均而言，股票研究分析师预测 MaxCyte, Inc.在当前财年将发布-0.42 的每股收益。</p>
</div><h2>Analyst Ratings Changes</h2>
<div class="lb-trans"><h2>分析师评级变动</h2>
</div><p>Several analysts recently issued reports on the company. Wall Street Zen downgraded MaxCyte from a &#34;hold&#34; rating to a &#34;sell&#34; rating in a report on Saturday, August 9th. Stephens began coverage on shares of MaxCyte in a research report on Tuesday, July 22nd. They issued an &#34;overweight&#34; rating and a $6.00 price objective for the company. BTIG Research reissued a &#34;neutral&#34; rating on shares of MaxCyte in a research report on Monday, August 11th. William Blair cut shares of MaxCyte from an &#34;outperform&#34; rating to a &#34;market perform&#34; rating in a research report on Thursday, August 7th. Finally, Weiss Ratings reissued a &#34;sell (d-)&#34; rating on shares of MaxCyte in a research report on Tuesday, October 14th. Two research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of &#34;Hold&#34; and an average target price of $7.00.</p>
<div class="lb-trans"><p>几位分析师最近对该公司发布了报告。华尔街 Zen 在 8 月 9 日星期六将 MaxCyte 的评级从 “持有” 下调至 “卖出”。Stephens 在 7 月 22 日星期二的研究报告中开始覆盖 MaxCyte 的股票。他们给予了 “增持” 评级，并设定了 6.00 美元的目标价。BTIG Research 在 8 月 11 日星期一的研究报告中重新发布了 MaxCyte 的 “中性” 评级。William Blair 在 8 月 7 日星期四的研究报告中将 MaxCyte 的股票评级从 “跑赢大盘” 下调至 “市场表现”。最后，Weiss Ratings 在 10 月 14 日星期二的研究报告中重新发布了 MaxCyte 的 “卖出（d-）” 评级。两位研究分析师对该股票给予了买入评级，两位给予了持有评级，一位给予了卖出评级。根据 MarketBeat 的数据，该股票目前的平均评级为 “持有”，平均目标价为 7.00 美元。</p>
</div><p><strong>Check Out Our Latest Stock Analysis on MaxCyte</strong></p>
<div class="lb-trans"><p><strong>查看我们对 MaxCyte 的最新股票分析</strong></p>
</div><h2>About MaxCyte</h2>
<div class="lb-trans"><h2>关于 MaxCyte</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>MaxCyte, Inc, a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering.</p>
<div class="lb-trans"><p>MaxCyte, Inc.是一家生命科学公司，在美国和国际上发现、开发和商业化下一代细胞疗法。其产品包括 ExPERT ATx，一种用于小到中型规模转染的静态电穿孔仪；ExPERT STx，一种用于蛋白质生产和药物开发的流动电穿孔仪，以及用于细胞基础检测的治疗靶标表达；ExPERT GTx，一种用于治疗应用的大规模转染的流动电穿孔仪；以及 ExPERT VLx，用于非常大体积的细胞工程。</p>
</div><h2>Recommended Stories</h2>
<div class="lb-trans"><h2>推荐阅读</h2>
</div><ul>
<li>Five stocks we like better than MaxCyte</li>
<li>Investing In Preferred Stock vs. Common Stock</li>
<li>Louis Vuitton Earnings Show Luxury Bull Market Isn’t Done Yet</li>
<li>How to Use the MarketBeat Dividend Calculator</li>
<li>3 High-Yield Banks for Investors to Buy on the Dip</li>
<li>What Are Some of the Best Large-Cap Stocks to Buy?</li>
<li>5 Surprising Stocks Set to Benefit From a Future Robotics Boom</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更喜欢的五只股票胜过 MaxCyte</li>
<li>投资优先股与普通股的比较</li>
<li>路易威登财报显示奢侈品牛市尚未结束</li>
<li>如何使用 MarketBeat 股息计算器</li>
<li>3 家高收益银行供投资者在下跌时购买</li>
<li>一些最佳的大盘股有哪些？</li>
<li>5 只意外受益于未来机器人热潮的股票</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TVhDVA" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=MXCT"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in MaxCyte Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 MaxCyte 吗？</h2>
</div><p>Before you consider MaxCyte, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 MaxCyte 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and MaxCyte wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 MaxCyte 并不在名单上。</p>
</div><p>While MaxCyte currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 MaxCyte 目前在分析师中被评为持有评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Chevy Chase Trust Holdings LLC 出售了 MaxCyte, Inc. $MXCT 的股票